Shared microglial mechanisms underpinning depression and chronic fatigue syndrome and their comorbidities.
Chaves-Filho, Adriano José Maia, Macedo, Danielle S, de Lucena, David Freitas et al. · Behavioural brain research · 2019 · DOI
Quick Summary
This review examined how depression and ME/CFS might share common causes in the brain, specifically through immune cells called microglia. Researchers found that when these brain immune cells become overactive, they may trigger both depression and the fatigue characteristic of ME/CFS. The study suggests that reducing this immune activation could potentially help treat both conditions.
Why It Matters
This review proposes a unifying biological mechanism—microglial activation and neuroinflammation—that could explain why depression and ME/CFS frequently occur together. If validated, it could shift treatment approaches from managing symptoms separately to targeting the shared immune dysfunction underlying both conditions, potentially improving outcomes for patients with comorbid depression and ME/CFS.
Observed Findings
Depressed patients show neuroinflammatory alterations consistent with microglial activation
Animal models exposed to lipopolysaccharides (bacterial endotoxins) develop microglial responses accompanied by depressive-like behaviors
Activated microglia appear to initiate fatigue in chronic inflammatory conditions, including infections and aging
Increased translocation of Gram-negative bacteria and elevated pro-inflammatory cytokines (e.g., IL-1) are associated with both depression and ME/CFS
Major depression and ME/CFS show strong co-occurrence, with fatigue and somatic symptoms being key features of depression
Inferred Conclusions
Shared immune-inflammatory pathways, particularly microglial activation, likely underpin the comorbidity of depression and ME/CFS
Microglial activation and neuroinflammation are promising therapeutic targets for treating overlapping manifestations of both conditions
The microglial response to immune challenges may represent a common biological mechanism explaining why fatigue and depression frequently coexist
Remaining Questions
Do human patients with comorbid depression and ME/CFS show elevated microglial activation simultaneously in both conditions, and can this be reliably measured in living patients?
What This Study Does Not Prove
This systematic review does not prove that microglial activation directly causes depression or ME/CFS in humans, as most evidence comes from animal models and indirect clinical markers. It does not establish whether microglial activation is primary (initiating disease) or secondary (resulting from other pathological processes), and cannot confirm that reducing microglial activation will effectively treat these conditions in patients. The review correlates microglial activity with symptoms but does not demonstrate causation through controlled human trials.
Does reducing microglial activation in humans actually improve both depressive and fatigue symptoms, and which anti-inflammatory interventions are most effective?
Is microglial activation the primary driver of symptom development or a secondary response to other pathological processes in depression and ME/CFS?
Are there specific microglial activation phenotypes that preferentially drive fatigue versus depression, or do they share identical mechanisms?